Hemab Therapeutics vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sutacimig entering registration study 2026 for Glanzmann thrombasthenia — zero approved prophylactics.
About
Hemab Therapeutics is a rare disease biotechnology company developing treatments for rare bleeding disorders that have no approved prophylactic options. The company raised $157 million in an oversubscribed Series C in October 2025, led by Sofinnova Partners and the Qatar Investment Authority (QIA) — a sovereign wealth fund's direct biotech investment signals strategic medical technology interest alongside financial return.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.